Genetics, diagnostics and therapeutic advances in NAFLD (original) (raw)

In 2014, NAFLD was confirmed as the fastest growing aetiology for hepatocellular cancer in the USA. However, 2014 also saw progress in our understanding of the heritability and pathogenesis of NAFLD, and an important clinical trial targeting the farnesoid X receptor pathway has illustrated advances in developing a pharmacological therapy.

References

  1. Neuschwander-Tetri, B. A. et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52, 913–924 (2010).
    Article CAS Google Scholar
  2. Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686–690 (2013).
    Article CAS Google Scholar
  3. Dunn, W. et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am. J. Gastroenterol. 103, 2263–2271 (2008).
    Article Google Scholar
  4. Siddiqui, M. S. et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis associate with atherogenic lipoprotein profile. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2014.10.008.
  5. Rosenson, R. S., Otvos, J. D. & Freedman, D. S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90, 89–94 (2002).
    Article CAS Google Scholar
  6. Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46, 352–356 (2014).
    Article CAS Google Scholar
  7. Mittal, S. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma: consider the population. J. Clin. Gastroenterol. 47 (Suppl.), S2–S6 (2013).
    Article Google Scholar
  8. Wong, R. J., Cheung, R. & Ahmed, A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59, 2188–2195 (2014).
    Article Google Scholar
  9. Bastati, N. et al. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 271, 739–747 (2014).
    Article Google Scholar
  10. Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(14)61933-4.

Download references

Acknowledgements

This work of the authors is supported in part by a grant from the NIH T32 DK 07150 and RO1 DK 81410 to A.J.S.

Author information

Authors and Affiliations

  1. Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Arkes Pavillion, 14-005, Chicago, 60527, IL, USA
    Mary E. Rinella
  2. VCU School of Medicine, Virginia Commonwealth University, Box 980341, Richmond, 23298-0341, VA, USA
    Arun J. Sanyal

Authors

  1. Mary E. Rinella
  2. Arun J. Sanyal

Corresponding author

Correspondence toArun J. Sanyal.

Ethics declarations

Competing interests

M.E.R. has served as a consultant to AbbVie, Fibrogen, Genentech, NGM Biopharmaceuticals and Takeda, W.L. Gore and Associates. A.J.S. has stock options in Genfit. He has served as a consultant to AbbVie, Astra Zeneca, Exhalenz, Fibrogen, Genfit, Immuron, Nimbus, Nitto Denko, Salix, Takeda and Tobira. He has been an unpaid consultant to Intercept and Echosens. His institution has received grant support from Gilead, Novartis, Salix, and Tobira.

PowerPoint slides

Rights and permissions

About this article

Cite this article

Rinella, M., Sanyal, A. Genetics, diagnostics and therapeutic advances in NAFLD.Nat Rev Gastroenterol Hepatol 12, 65–66 (2015). https://doi.org/10.1038/nrgastro.2014.232

Download citation